A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas

European Journal of Endocrinology

Volumn 139, Issue 1, 1998, Pages 78-83

  Kayath, Marcia J ^a   Martin, Luciana C ^a   Vieira, José Gilberto H ^a   Roman, Leonor M ^a   Nosé Alberti, Vânia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UREMIA;

EID: 0031856613     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390078     Document Type: Article

References (32)

1. Arnold A, Staunton CE, Kim HG, Gaz RD & Kronenberg HM. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. New England Journal of Medicine 1988 318 658-662.
2. Arnold A & Kim HG. Clonal loss of one chromosome 11 in a parathyroid adenoma. Journal of Clinical Endocrinology and Metabolism 1989 69 496-499.
3. Friedman E, Bale AE, Marx SJ, Norton JA, Arnold A, Tu T et al. Genetic abnormalities in sporadic adenomas. Journal of Clinical Endocrinology and Metabolism 1989 71 293-297.
4. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM & Spurr NK. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. New England Journal of Medicine 1989 321 218-224.
5. Hsi ED, Zukerberg LR, Yang WI & Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism 1996 81 1736-1739.
6. Cryns V, Thor A, Xu H, Hu SX, Wierman MB, Vickery AL Jr et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New England Journal of Medicine 1994 330 757-761.
7. Subramanian P, Wilkinson S & Shepherd JJ. Inactivation of retinoblastoma gene in malignant parathyroid growths: a candidate genetic trigger? Australian and New Zealand Journal of Surgery 1995 65 714-716.
8. Chen PL, Chen YM, Bookstein R & Lee WH. Genetic mechanisms of tumour suppression by the human p53 gene. Science 1990 250 1576-1580.
9. Velculescu VE & El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clinical Chemistry 1996 42 858-868.
10. Harris CC & Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New England Journal of Medicine 1993 329 1318-1327.
11. Cryns VL, Rubio MP, Thor AD, Louis DN & Arnold A. p53 abnormalities in human parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1994 78 1320-1324.
12. Subramaniam P, Wiikinson S & Shepherd JJ. p53 tumor suppressor gene expression in hyperparathyroidism. Australian and New Zealand Journal of Surgery 1996 66 302-304.
13. Wang W, Johansson H, Kvasnicka T, Farnebo L-O & Grimelius L. Detection of apoptotic cells and expression of Ki-67 antigen. Bcl-2, p53 oncoproteins in human parathyroid adenoma. APMIS 1996 104 789-796.
14. Vargas MP, Vargas HI, Kleiner DE & Merino MJ. The role of prognostic markers (MIB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Modern Pathology 1997 10 12-17.
15. Hakim JP & Levine MA. Absence of p53 point mutations in parathyroid adenoma and carcinoma. Journal of Clinical Endocrinology and Metabolism 1994 78 103-106.
16. DeLellis RA. Atlas Of Tumor Pathology: Tumors Of The Parathyroid Gland, third series. Washington DC: Armed Forces Institute of Pathology, 1991.
17. Grimelius L & Bondenson L. Histological diagnosis of parathyroid diseases. Pathology Research and Practice 1995 191 353-365.
18. Falcheti A, Bale AE, Amorosi A, Bordi C, Cicchi P & Bandini S. Progression of uremic hyperparathyroidism involves allelic loss of chromosome 11. Journal of Clinical Endocrinology and Metabolism 1993 76 139-144.
19. Vieira JGH, Nishida SK, Kasamatsu, Amarante EC & Kunii IS. Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Brazilian Journal of Medical and Biological Research 1994 27 2379-2382.
20. Hsu SM. Raine L & Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. Journal of Histochemistry and Cytochemistry 1981 29 577-580.
21. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, MacGeogh C & Spurr NK. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992 340 259-263.
22. Lehman TA, Bennet WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ulrich S, Romano JW, Appella E & Testa JR. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Research 1991 51 4090-4096.
23. Momand J, Zambetti GP, Olson DC, George D & Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992 69 1237-1245.
24. Oliner JD, Kinzler KW, Meltzer PS, George DL & Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992 358 80-83.
25. Thomas DW. p53 in tumour pathology: can we trust immunocytochemistry? Journal of Pathology 1992 166 329-330.
26. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997 88 323-331.
27. Wang XW & Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. Journal of Cellular Physiology 1997 173 247-255.
28. Lee Y-S & Teh M. p53 expression in pseudoepitheliomatous hyperplasia keratoaeanthoma, and squamous cell carcinoma of skin. Cancer 1994 73 2317-2323.
29. Dei Tos AP, Doglioni C, Laurino L, Barbareschi M & Fletcher CD. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology 1993 22 45-50.
30. Wang LD, Hong JY, Qui SL, Gao H & Yang CS. Accumulation of p53 protein in esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Research 1993 53 1783-1787.
31. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B & Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Research 1992 51 6304-6311.
32. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Dour-Rasy S & Duvillard P. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metas-tases: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995 10 1217-1227.